AI
Friday, March 13, 2026 4:09:50 AM
Just recently published (19/02/2026)
US20260048124 - METHODS FOR TREATING BRAIN CANCER
Abstract
The current disclosure provides for a method for stratifying patients based on their predicted efficacy to an immunotherapy. Accordingly, provided herein is a method for treating a subject for brain cancer, the method comprising administering to the subject an immunotherapy, wherein the subject has been determined be negative or low for an interferon gamma activation response in a biological sample from the patient. Also described is a method for predicting patient outcomes and/or for predicting the effectiveness of an immunotherapy for treating brain cancer in a subject in need thereof, the method comprising determining an interferon gamma activation response from a biological sample from the subject. Also provided is a method for evaluating a subject having brain cancer, the method comprising determining an interferon gamma activation response in a biological sample from the subject.
ApplicantsTHE REGENTS OF THE UNIVERSITY OF CALIFORNIA :
Inventors:
Robert PRINS
Richard EVERSON
Willy HUGO
Linda LIAU
Most importantly:-
Within these Claims lies the 'recipe' for both the:-
Combo patent: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
https://clinicaltrials.gov/study/NCT04201873
and the
TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial
https://nature.com/articles/s41467-024-48073-y
14. The method of claim 13, wherein the dendritic cell vaccine comprises an autologous tumor lysate (ATL) DC vaccine.
25. The method of claim 24, wherein the TLR agonist comprises a TLR3 agonist and wherein the TLR3 agonist comprises polyinosinic acid polycytidylic acid stabilized with polylysine (poly-ICLC).
98. A method for treating a subject having brain cancer and that has been previously treated with a neoadjuvant cancer vaccine, the method comprising administering an adjuvant immunotherapy to the subject; wherein the subject has been determined to have a positive interferon activation response in a biological sample from the subject; wherein the immunotherapy comprises immune checkpoint inhibitor (ICI) therapy; and wherein the cancer vaccine comprises ATL-DC vaccine or neoantigen therapy.
28. The method of claim 27, wherein the TLR agonist comprises Imiquimod or Resiquimod.
17. The method of claim 1, wherein the immunotherapy comprises immune checkpoint inhibitor (ICI) therapy and wherein the ICI therapy comprises an inhibitor of PD-1, PDL1, PDL2, and/or CTLA-4.
1. A method for treating a subject for brain cancer, the method comprising administering to the subject an immunotherapy, wherein the subject has been evaluated for an interferon activation response in a biological sample from the subject.
2. The method of claim 1, wherein the brain cancer comprises glioma.
3- 8. (canceled)
9. The method of claim 1, wherein the subject has previously been treated with an anti-cancer therapy and wherein the anti-cancer therapy comprises a TLR agonist, neoadjuvant therapy, and/or an immunotherapy.
10. (canceled)
11. The method of claim 1, wherein the subject has been treated, will be treated, or is being treated with one or both of a TLR agonist and an immunotherapy and wherein the immunotherapy comprises a cancer vaccine.
12. (canceled)
13. The method of claim 11, wherein the cancer vaccine comprises a dendritic cell (DC) vaccine or neoantigen therapy.
14. The method of claim 13, wherein the dendritic cell vaccine comprises an autologous tumor lysate (ATL) DC vaccine.
15- 16. (canceled)
17. The method of claim 1, wherein the immunotherapy comprises immune checkpoint inhibitor (ICI) therapy and wherein the ICI therapy comprises an inhibitor of PD-1, PDL1, PDL2, and/or CTLA-4.
18- 21. (canceled)
22. The method of claim 17, wherein the ICI therapy comprises ipilimumab and nivolumab.
23. The method of claim 11, wherein the immunotherapy is an adjuvant therapy.
24. The method of claim 9, wherein the TLR agonist comprises a TLR3, TLR7, TLR8, and/or TLR7/8 TLR agonist.
25. The method of claim 24, wherein the TLR agonist comprises a TLR3 agonist and wherein the TLR3 agonist comprises polyinosinic acid polycytidylic acid stabilized with polylysine (poly-ICLC).
26. (canceled)
27. The method of claim 24, wherein the TLR agonist comprises a TLR7 or TLR7/8 agonist.
28. The method of claim 27, wherein the TLR agonist comprises Imiquimod or Resiquimod.
29. The method of claim 1, wherein the biological sample comprises peripheral blood mononuclear cells (PBMCs).
30. The method of claim 1, wherein the interferon activation response comprises a GSVA score of greater than 0 for a IFNg gene set or IFNa gene set.
31. (canceled)
32. The method of claim 1, wherein the biological sample is from a subject that received a cancer vaccine at a time point of 0-24 hours prior to the collection of the biological sample.
33. The method of claim 30, wherein the GSVA score is a score based on the interferon gene set of Table 3, 4, or 5, or any combinations of genes therein.
34. A method for: (i) predicting subject outcomes and/or for predicting the effectiveness of an immunotherapy for treating brain cancer in a subject in need thereof; (ii) monitoring a subject having brain cancer and being treated with an immunotherapy; or (iii) evaluating a subject having brain cancer; the method comprising determining an interferon activation response from a biological sample from the subject.
35- 97. (canceled)
98. A method for treating a subject having brain cancer and that has been previously treated with a neoadjuvant cancer vaccine, the method comprising administering an adjuvant immunotherapy to the subject; wherein the subject has been determined to have a positive interferon activation response in a biological sample from the subject; wherein the immunotherapy comprises immune checkpoint inhibitor (ICI) therapy; and wherein the cancer vaccine comprises ATL-DC vaccine or neoantigen therapy.
99. The method of claim 1, wherein the subject is a human subject.
US20260048124 - METHODS FOR TREATING BRAIN CANCER
Abstract
The current disclosure provides for a method for stratifying patients based on their predicted efficacy to an immunotherapy. Accordingly, provided herein is a method for treating a subject for brain cancer, the method comprising administering to the subject an immunotherapy, wherein the subject has been determined be negative or low for an interferon gamma activation response in a biological sample from the patient. Also described is a method for predicting patient outcomes and/or for predicting the effectiveness of an immunotherapy for treating brain cancer in a subject in need thereof, the method comprising determining an interferon gamma activation response from a biological sample from the subject. Also provided is a method for evaluating a subject having brain cancer, the method comprising determining an interferon gamma activation response in a biological sample from the subject.
ApplicantsTHE REGENTS OF THE UNIVERSITY OF CALIFORNIA :
Inventors:
Robert PRINS
Richard EVERSON
Willy HUGO
Linda LIAU
Most importantly:-
Within these Claims lies the 'recipe' for both the:-
Combo patent: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
https://clinicaltrials.gov/study/NCT04201873
and the
TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial
https://nature.com/articles/s41467-024-48073-y
14. The method of claim 13, wherein the dendritic cell vaccine comprises an autologous tumor lysate (ATL) DC vaccine.
25. The method of claim 24, wherein the TLR agonist comprises a TLR3 agonist and wherein the TLR3 agonist comprises polyinosinic acid polycytidylic acid stabilized with polylysine (poly-ICLC).
98. A method for treating a subject having brain cancer and that has been previously treated with a neoadjuvant cancer vaccine, the method comprising administering an adjuvant immunotherapy to the subject; wherein the subject has been determined to have a positive interferon activation response in a biological sample from the subject; wherein the immunotherapy comprises immune checkpoint inhibitor (ICI) therapy; and wherein the cancer vaccine comprises ATL-DC vaccine or neoantigen therapy.
28. The method of claim 27, wherein the TLR agonist comprises Imiquimod or Resiquimod.
17. The method of claim 1, wherein the immunotherapy comprises immune checkpoint inhibitor (ICI) therapy and wherein the ICI therapy comprises an inhibitor of PD-1, PDL1, PDL2, and/or CTLA-4.
1. A method for treating a subject for brain cancer, the method comprising administering to the subject an immunotherapy, wherein the subject has been evaluated for an interferon activation response in a biological sample from the subject.
2. The method of claim 1, wherein the brain cancer comprises glioma.
3- 8. (canceled)
9. The method of claim 1, wherein the subject has previously been treated with an anti-cancer therapy and wherein the anti-cancer therapy comprises a TLR agonist, neoadjuvant therapy, and/or an immunotherapy.
10. (canceled)
11. The method of claim 1, wherein the subject has been treated, will be treated, or is being treated with one or both of a TLR agonist and an immunotherapy and wherein the immunotherapy comprises a cancer vaccine.
12. (canceled)
13. The method of claim 11, wherein the cancer vaccine comprises a dendritic cell (DC) vaccine or neoantigen therapy.
14. The method of claim 13, wherein the dendritic cell vaccine comprises an autologous tumor lysate (ATL) DC vaccine.
15- 16. (canceled)
17. The method of claim 1, wherein the immunotherapy comprises immune checkpoint inhibitor (ICI) therapy and wherein the ICI therapy comprises an inhibitor of PD-1, PDL1, PDL2, and/or CTLA-4.
18- 21. (canceled)
22. The method of claim 17, wherein the ICI therapy comprises ipilimumab and nivolumab.
23. The method of claim 11, wherein the immunotherapy is an adjuvant therapy.
24. The method of claim 9, wherein the TLR agonist comprises a TLR3, TLR7, TLR8, and/or TLR7/8 TLR agonist.
25. The method of claim 24, wherein the TLR agonist comprises a TLR3 agonist and wherein the TLR3 agonist comprises polyinosinic acid polycytidylic acid stabilized with polylysine (poly-ICLC).
26. (canceled)
27. The method of claim 24, wherein the TLR agonist comprises a TLR7 or TLR7/8 agonist.
28. The method of claim 27, wherein the TLR agonist comprises Imiquimod or Resiquimod.
29. The method of claim 1, wherein the biological sample comprises peripheral blood mononuclear cells (PBMCs).
30. The method of claim 1, wherein the interferon activation response comprises a GSVA score of greater than 0 for a IFNg gene set or IFNa gene set.
31. (canceled)
32. The method of claim 1, wherein the biological sample is from a subject that received a cancer vaccine at a time point of 0-24 hours prior to the collection of the biological sample.
33. The method of claim 30, wherein the GSVA score is a score based on the interferon gene set of Table 3, 4, or 5, or any combinations of genes therein.
34. A method for: (i) predicting subject outcomes and/or for predicting the effectiveness of an immunotherapy for treating brain cancer in a subject in need thereof; (ii) monitoring a subject having brain cancer and being treated with an immunotherapy; or (iii) evaluating a subject having brain cancer; the method comprising determining an interferon activation response from a biological sample from the subject.
35- 97. (canceled)
98. A method for treating a subject having brain cancer and that has been previously treated with a neoadjuvant cancer vaccine, the method comprising administering an adjuvant immunotherapy to the subject; wherein the subject has been determined to have a positive interferon activation response in a biological sample from the subject; wherein the immunotherapy comprises immune checkpoint inhibitor (ICI) therapy; and wherein the cancer vaccine comprises ATL-DC vaccine or neoantigen therapy.
99. The method of claim 1, wherein the subject is a human subject.
#dcvax $nwbo #gbm
— Peter Davis (@peter_brit) March 13, 2026
Just recently published (19/02/2026)
US20260048124 - METHODS FOR TREATING BRAIN CANCER
Abstract
The current disclosure provides for a method for stratifying patients based on their predicted efficacy to an immunotherapy. Accordingly, provided herein is a… pic.twitter.com/YJ0C9tP7EP
Bullish
